Key points are not available for this paper at this time.
To estimate projected US-based cost and time burden for patients with myelofibrosis and anemia treated with momelotinib compared with danazol.
Share your take
Add a clinician perspective alongside expert commentary.
Masárová et al. (2024) studied this question.